Spain Onychomycosis Market Insights Forecasts to 2033

• The Spain Onychomycosis Market Size was valued at USD 68.1 Million in 2023.
• The Market is Growing at a CAGR of 4.62% from 2023 to 2033
• The Spain Onychomycosis Market Size is Expected to Reach USD 105.4 Million by 2033

The Spain Onychomycosis Market is Anticipated to Reach USD 105.4 Million by 2033, growing at a CAGR of 4.62% from 2023 to 2033.

Market Overview

Onychomycosis, also known as nail fungus or tinea unguium, is a fungal infection that can affect the nail plate, nail matrix, or nail bed. It is more likely to affect toenails than fingernails and is the most common nail condition. In Spain, the period prevalence of onychomycosis was 2.6% and the point prevalence was 1.7%. The prevalence was higher in women (1.8%) than in men (0.8%), and the oldest age group (> 55 years) showed a higher prevalence (1.2%). The increasing cases of fungal nail infection are attributed to the aging population, growing diabetes cases, and the rising rate of conditions that weaken the immune system, fuelling the growth of the Spain onychomycosis market.

Report Coverage

This research report categorizes the market for the Spain onychomycosis based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Spain onychomycosis market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Spain onychomycosis market.

Driving Factors

Advancements in treatments, such as improvements in novel oral antifungals, laser treatments, and topical therapies, are driving the growth of the market. Factors such as better efficiency, improved patient compliance, and reduced side effects are contributing to this growth. Additionally, increased healthcare expenses, particularly in developing economies, are improving access to better treatments as healthcare systems continue to improve. As a result, the availability of these treatments is increasing. Furthermore, the growing awareness of the condition among patients and the knowledge of advanced treatments among healthcare professionals are leading to an increasing number of diagnoses.

Restraining Factors

Some treatments may not be effective for all types of patients or may have a higher rate of recurrence of the same disease. The effectiveness of treatment may vary depending on the type and severity of the infection, which highlights the need for ongoing research and development. Diagnosing onychomycosis may be challenging for healthcare professionals because the symptoms often overlap with other nail disorders. Therefore, a delay in diagnosis could result in delayed treatment, potentially worsening the infection and making it more difficult to manage.

Market Segmentation

The Spain onychomycosis market share is classified into type and treatment.

• The distal subungual onychomycosis segment is expected to hold the largest market share through the forecast period.

The Spain onychomycosis market is segmented by type into distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis, and others. Among these, the distal subungual onychomycosis segment is expected to hold the largest market share through the forecast period.  This type of fungal infection affects the nail bed and the underside of the nail, typically starting at the tip and gradually spreading towards the cuticle. Distal subungual onychomycosis is the most common form of onychomycosis, accounting for a significant portion of diagnosed cases in Spain. It is often associated with dermatophyte fungi and can result in nail discoloration, thickening, and deformities.

• The topical segment is expected to dominate the Spain onychomycosis market during the forecast period.       

Based on the treatment, the Spain onychomycosis market is divided into topical, oral, and others. Among these, the topical segment is expected to dominate the Spain onychomycosis market during the forecast period. Topical treatments have fewer severe side effects, but they also have lower cure rates and require much longer treatment periods. New topical formulations are also being researched as faster-acting alternatives to already available topical therapies. However, topical formulations have low cure rates and are ineffective since they are unable to penetrate the nail plate to reach the diseased nail bed in sufficient concentrations to kill the fungus, thus debridement of the nail plate may be required before administration.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Spain onychomycosis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

List of Key Companies

• Bausch Health Companies Inc
• Sun Pharmaceutical Industries
• Bayer AG
• GSK PLC
• Cipla Ltd DR
• Merck & Co Inc
• Pfizer Inc
• Abbott Laboratories
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In November 2022, REIG JOFRE, a pharmaceutical company listed on the Spanish stock exchange, introduced a medicated nail lacquer for onychomycosis (fungal nail infection) developed by its innovation team, manufactured at the Barcelona plant with CicloTech, the new patented trans-ungual release technology and marketed by REIG JOFRE.

Market Segment

This study forecasts revenue at Spain, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Spain Onychomycosis Market based on the below-mentioned segments:

Spain Onychomycosis Market, By Type

• Distal Subungual Onychomycosis
• Proximal Subungual Onychomycosis
• White Superficial Onychomycosis
• Others

Spain Onychomycosis Market, By Treatment

• Topical
• Oral
• Others